ENTX - Entera Bio Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.2300
0.0000 (0.00%)
At close: 1:47PM EDT
Stock chart is not supported by your current browser
Previous Close4.2300
Open3.9718
Bid0.0001 x 1300
Ask6.0000 x 1800
Day's Range3.9718 - 4.2300
52 Week Range2.5500 - 7.6000
Volume50
Avg. Volume26,391
Market Cap48.342M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.3790
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    Entera Bio Announces a Transition in the Chief Financial Officer Position

    Entera Bio Ltd. (ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms. Rosenzweig has confirmed to us that she has no disagreement with the presentation of the Company’s financial statements or accounting policies. “The company appreciates Mira’s dedication and significant contributions to the progress at Entera over the past several years, including the completion of an IPO on the Nasdaq in July 2018.

  • GlobeNewswire2 months ago

    Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis

    Entera Bio Ltd. (ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis. The feedback and guidance were summarized in the formal meeting minutes that Entera subsequently received from the FDA.  In addition to discussing various aspects of the nonclinical and clinical development plan, the meeting focused on the 505 b(2) regulatory pathway and the use of bone mineral density (BMD) rather than fracture incidence as the primary endpoint to support a New Drug Application (NDA). Based on the FDA's response, Entera believes that the Phase 3 study may use BMD as the primary efficacy endpoint and that a fracture endpoint study will not be required.

  • GlobeNewswire2 months ago

    Entera Bio Reports Third Quarter 2018 Financial Results and Operating Update

    Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial salesMet with.

  • GlobeNewswire2 months ago

    Entera Bio Appoints Gerald M. Ostrov to Board of Directors

    JERUSALEM, Jan. 10, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors,.

  • GlobeNewswire3 months ago

    Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

    Entera Bio Ltd. (ENTX) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.